Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib vs Chemotherapy in First-line Uncommon EGFR Mutation NSCLC
NCT04951648Phase 3Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04951648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951648.